Shots:

• QurAlis in-licenses Eli Lilly’s excitotoxicity targeted pre-clinical compounds with disease-modifying potential in ALS
• The collaboration allows QurAlis to foster its ALS Pipeline with the addition of Lilly’s pre-clinical candidates
• QurAlis’ excitotoxicity research program aims to prevent neuronal excitability with specifically targeted small molecule drugs and prevent disease progression in ALS patients

Click here to read full press release/ article

Ref: PRNewswire | Image: Eli Lilly